German Mesothelioma Register



Similar documents
German Social Accident Insurance, DGUV, Germany

Riga Centre of Psychiatry and Addiction Medicine, Latvia

Rehabilitation and MS-Centre Overpelt, Belgium

Entidade Reguladora da Saúde ERS (Portuguese Health Regulatory Authority), Portugal

Groupe MGEN - Mutuelle Générale de l'education Nationale, France

Ministère des Affaires Sociales et de la Santé, France

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

Board of Member States ERN implementation strategies

Asbestos is a fibrous mineral that has been used in Europe as electrical and heat insulation, reinforcing concrete and polymers, sound insulation

The Belgian Asbestos Fund

SUBJECT: MUNICIPAL MUTUAL INSURANCE SCHEME OF ARRANGEMENT UPDATE

EPF Position Statement on the European Commission s proposal for a Regulation on In Vitro Medical Devices

CLAIM FORM & DECLARATION FOR THE J T THORPE COMPANY SUCCESSOR TRUST

Questions and Answers about the prevention of occupational diseases

A&I Asbestos Trust Claim Form

Screening for asbestos-related lung cancer Nea Malila, Tony Miller, Riitta Sauni, Robert Smith, Kurt Straif, Tapio Vehmas

COMMISSION OF THE EUROPEAN COMMUNITIES

FREQUENTLY ASKED QUESTIONS about asbestos related diseases

No. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008

A-Best Asbestos PI Trust Claim Form

- Compensation issues

Asbestos related disease compensation. no-one can change the past, but one of us could change your future

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010

PREVENTION OF OCCUPATIONAL DISEASES

Government lump sum payments for mesothelioma and other lung diseases

A.P.I. CLAIM FORM Page 1 A.P.I., INC. ASBESTOS SETTLEMENT TRUST

Asbestos Brochure. Jim Wyatt - jwyatt@hamers.com Stephen Ball - sball@hamers.com. Freephone:

Healthcare Science Programme Guide

Exigency Hardship Claim. Last Name First Name Middle Name Suffix. Last Name First Name Middle Name Suffix. Last Name First Name Middle Name Suffix

Health and Social Care Committee Recovery of Medical Costs for Asbestos Diseases (Wales) Bill RMCA12 Forum of Insurance Lawyers

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases

Other Asbestos Disease (Level I) Asbestosis/Pleural Disease (Level II) Asbestosis/Pleural Disease (Level III)

Asbestos Diseases Uncovered

TO BE COMPLETED IF MESOTHELIOMA IS DIAGNOSED OR SUSPECTED NOT TO BE RELEASED WITHOUT PATIENT/NEXT OF KIN S PERMISSION

Acting Together: How to continue to provide high quality and universally accessible health services in a financially sustainable way in Europe.

On April 6, 2004, a Board Hearing Officer confirmed the Case Manager s findings.

ACandS Asbestos Settlement Trust Claim Form

BIOSCIENCES COURSE TITLE AWARD

Molecular Biotechnology Master s Degree Program

Burns and Roe Asbestos Personal Injury Settlement Trust Claim Form

A BILL for AN ACT. Serial 137 Personal Injuries (Civil Claims) Bill 2003 Dr Toyne

Asbestos Diseases. What Is Asbestos?

United Gilsonite Laboratories Asbestos Personal Injury Trust

Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Other Asbestos Disease (Level I) Asbestosis/Pleural Disease (Level II) Asbestosis/Pleural Disease(Level III)

ARTRA 524(g) Asbestos Trust Claim Form

Review of Eliminating occupational cancer in Europe and globally by J. Takala

How To Prevent Asbestos Related Diseases

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Kaiser Aluminum & Chemical Asbestos PI Trust Claim Form

Programme Specification 2015/16

PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON*

ASARCO Asbestos Personal Injury Settlement Trust

BABCOCK & WILCOX COMPANY ASBESTOS PERSONAL INJURY SETTLEMENT TRUST PROOF OF CLAIM FORM

ERA-Net COFUND Research Programmes on Rare Diseases (E-RARE)

Plibrico Asbestos Trust Claim Form

Mesothelioma and other lung diseases

Biomarkers for early detection of asbestosassociated

ENS4Care Questionnaire

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

FEDERAL-MOGUL ASBESTOS PERSONAL INJURY TRUST PROOF OF CLAIM FORM

PRIMARY LUNG CANCER TREATMENT

Lung cancer and asbestos

Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment

ABB LUMMUS GLOBAL INC. 524(g) ASBESTOS PI TRUST PROOF OF CLAIM FORM FOR LUMMUS NON-FEEDWATER HEATER CLAIMS

KAISER ALUMINUM & CHEMICAL CORPORATION ASBESTOS PERSONAL INJURY TRUST

Today s Health Research Is Tomorrow s Healthcare

FBU ASBESTOS DATABASE

Complementary Cancer Care Trust Information and Supportive Therapies For People with Life-affecting Illnesses Registered Charity

Third EU Health Programme

Hamers S O L I C I T O R S. Jim Wyatt jwyatt@hamers.com. Freephone: Earls Court, Priory Park, East, Hull HU4 7DY

DII INDUSTRIES, LLC ASBESTOS PI TRUST PROOF OF CLAIM FORM

The EFPIA Disclosure Code: Your Questions Answered

G-I Holdings Inc. Asbestos Personal Injury Settlement Trust

USG ASBESTOS PERSONAL INJURY SETTLEMENT TRUST PROOF OF CLAIM FORM

ASARCO Asbestos Personal Injury Settlement Trust. Claims Audit Program Adopted Under TDP

Armstrong World Industries, Inc. ASBESTOS PERSONAL INJURY SETTLEMENT TRUST PROOF OF CLAIM FORM

Lung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group

HEALTH CARE FOR EXPOSURE TO ASBESTOS The SafetyNet Centre for Occupational Health and Safety Research Memorial University

types listed below which the law firm relied upon in submitting the medical and exposure information for the subject claim.

Male. Female. Death rates from lung cancer in USA

Transcription:

German Mesothelioma Register 1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation: 1. Respondent Profile Academic/public health and healthcare specialised institution/organisation (e.g. Institutes and University Departments of Public Health, Quality, Healthcare, Clinical Excellence) Please indicate level: National level organisation Please indicate for what the administration is responsible: 1.1.1. Other (please specify): Public/contracted center: German Statutory Insurance (DGUV) 1.2 Please indicate the name of your organisation or centre: German Mesothelioma Register 1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe: DE 1.4 Please indicate the number of EU Member States and EEA countries (rway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented: 1. If need be, can we contact you by e-mail to obtain further information on your submission? 1..1 Please provide an e-mail address where we can contact you: andrea.tannapfel@rub.de 10 Yes 1.6 Please provide us with a contact person (incl jobtitle and daytime phone number): Professor Andrea Tannapfel Phone: +49 234 302 4800 Fax: +49-234 302 4809

1.7 Please provide additional contact details if needed: 2. Involvement of your organisation in the matter of centres of excellence/reference (COE) and healthcare networks in highly specialised healthcare (HSHC). 2.1 How would you describe your organisation's knowledge of CoE and HSHC? Very high 2.1.1 Space for further comments: The German Mesothelioma Register constitutes as a national reference center for the diagnosis of mesothelioma and pneumoconioses. 2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies) Highly specialised healthcare provision Professional performance, clinical practice, quality and safety of specialized healthcare 2.2.1. Space for further comments: 2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans? 2.3.1 Space for further comments: 2.4. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work? High Laboratories and central services (e.g. pathology, genetics, biochemistry, pharmacy, microbiology etc.) Please specify: 2.. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare? Guidelines for occupational diseases Frequently 2..1 Please describe your role in such actions/projects: Participation in national guidelines for diagnosis, treatment and evaluation of diseases of the lung and pleura.

2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare? 2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/coe or HSHC (e.g. quality criteria, guidelines, consensus documents)? Yes 2.7.1 Space for further comments: Guideline (S2 AWMF) Diagnostics and Expert opinion of Asbestos induced occupational diseases Nº. 4103-410: Guideline 2011 Guideline (S2 AWMF) Idem Occupational Disease Nº4101 Silicosis 2.13. What is the scope of the network? 2.14. Which kind of network? 2.14.1 Space for further comments: 2.1. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, = very interested) 2.1.1 Space for further comments: 3. Proposed criteria for ERN (scope, general and specific criteria) 3.1 Criteria related with diseases or conditions in order to be considered under the scope of the ERN 3.1.1. Need of highly specialised healthcare 3.1.1.1. Complexity of the diagnosis and treatment

3.1.1.2. High cost of treatment and resources 3 3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures 3.1.2. Need of particular concentration of expertise and resources 4 3.1.2.1. Rare expertise/need of concentration of cases 4 3.1.2.2. Low prevalence/incidence/number of cases 4 3.1.2.3. Evaluated experiences of Member States 4 3.1.3. Based on high-quality, accessible and cost-effective healthcare 4 3.1.3.1. Evidence of the safety and favourable risk-benefit analysis 3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical) 3.1.4. Do you recommend any additional criteria or option that would effectively address the issue? 3.1.. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria? 3.1..1 Explain your proposal in free text: Lung carcinoma is a leading cause of cancer related death. The diagnosis and the optimal therapy scheme for this disease have become very comples due to the ongoing evolvement of molecular biomarkers. Yes 3.2. General criteria of the centres wishing to join a European Reference Network

3.2.1. Organisation and management 3.2.2. Patients empowerment and centered care 4 3.2.3. Patient care, clinical tools and health technology assessment 4 3.2.4. Quality, patient safety and evaluation framework policies 4 3.2.. Business continuity, contingency planning and response capacity 3.2.6. Information systems, technology and e-health tools and applications 3.2.7. Overall framework and capacity for research and training 4 3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN 3.2.9. Do you recommend any additional option that would effectively address the issue? 3.2.9.1. Space for further comments: 3.3. Specific criteria regarding the areas of expertise 3.3.1. Competence, experience and good outcomes and care 3.3.2. Specific resources and organisation: 3.3.2.1. Human resources 3.3.2.2. Team/centre organisation

3.3.2.3. Structural conditions 4 3.3.2.4. Specific equipment 3.3.2.. Presence and coordination with other required complementary units or services 3.3.3. Patient care pathways, protocols and clinical guidelines in the field of expertise 3.3.4. External coordination, care management and follow-up of patients 3.3.. Research, training, health technology assessment in the field of expertise 3.3.6. Specific information systems 4 4 4 3.3.7. Do you recommend any additional criteria or option that would effectively address the issue? 3.3.7.1. Space for further comments: Research for rare disease like mesothelioma and asbestosis. Developement and update of gudelines for the diagnosis and therapy of this diseases.